An interventional study of Linear ablation and PVI alone in Persistent Atrial Fibrillation, sponsored by Boston Scientific Corporation. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Atrial Fibrillation by Boston Scientific Corporation — 8 open to participants now, 20 under way, none of them phase 3. Atrial Fibrillation · Boston Scientific Corporation.
Among the 73 studies in Atrial Fibrillation by Boston Scientific Corporation, this one is the 10th largest by planned enrollment of the 51 interventional ones that give a count, is one of 9 that started in 2025, is one of 45 with no phase, reaches primary completion later than 11 of the 19 other live ones, and was the 65th registered.
4,016 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.
Browse Atrial Fibrillation studies →8 of the 73 studies in Atrial Fibrillation by Boston Scientific Corporation are open now, in 11 countries. Recruiting first, the newest first:
Boston Scientific Corporation · Sites in United States
Ages 18+
Boston Scientific Corporation · Sites in United States, Belgium, Ireland and 1 more country
Ages 18+
Boston Scientific Corporation · Sites in Belgium, Croatia, France and 2 more countries
Ages 18+
Boston Scientific Corporation · Sites in Croatia, Czechia, Hong Kong and 1 more country
Ages 18+
Boston Scientific Corporation · Sites in Belgium, Croatia, Czechia and 1 more country
Ages 18+
By country, each count listing its studies:
Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 5 · Phase 4 1
First in 2002; this study’s year is marked. 9 started in 2025.
This study's planned enrollment of 640 is above the median of 150 across 2,479 interventional studies indexed under Atrial Fibrillation.
Median enrollment 200 across the 51 interventional studies, 332 across the 22 observational. Of the 50 that completed or were terminated, 33 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boston Scientific Corporation is the lead sponsor of 528 studies on the registry; 40 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 57 (88%) have results posted.
7 of the studies in Atrial Fibrillation by Boston Scientific Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07187115Boston Scientific CorporationA Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation | 2027-01 |
| NCT06510556Boston Scientific CorporationFeasibility Study of the FARAFLEX Mapping and PFA System | 2027-02-15 |
| NCT06656884Boston Scientific CorporationFARAPULSE Workflow Assessment Registry | 2027-02-15 |
| NCT06735534Boston Scientific CorporationRepeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | 2027-04 |
| NCT06808217Boston Scientific CorporationA Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 73 studies in Atrial Fibrillation by Boston Scientific Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to pulmonary vein isolation (PVI) outperforms PVI alone using pulsed field ablation (PFA) in maintaining sinus rhythm for persistent atrial fibrillation (PerAF)
This study is a prospective, multicenter, open-label, randomized controlled trial to investigate whether a linear ablation in addition to PVI outperforms PVI alone using PFA in maintaining sinus rhythm for PerAF. Enrolled subjects will be randomized by the ratio of 1:1 into PVI and linear ablation arm or PVI alone arm. Subjects in PVI and linear ablation arm will undergo bilateral PVI, and linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device and EIVOM could be performed additionally before or after PFA at the operator's discretion, it is recommended to perform EIVOM first. Subjects randomized to the PVI alone arm will undergo PVI only. If atrial fibrillation (AF) cannot be terminated during ablation, cardioversion will be performed. After ablation, all the subjects will be followed at discharge, 1 month and then at 3-month intervals up to 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study subjects are required to meet all the following inclusion criteria:
Subjects have symptomatic, drug-resistant, persistent AF, defined as:
Exclusion Criteria:
Any of the following events within 90 days of the Consent Date:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in PVI and linear ablation arm will undergo bilateral PVI, and linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device, and EIVOM could be performed additionally before or after PFA at the operator's discretion.
Procedure: Linear ablation · Procedure: PVI alone
Subjects randomized to the PVI alone arm will undergo PVI only with the study device.
Procedure: PVI alone
Linear ablations in the posterior wall (PW), mitral isthmus (MI) and cavo-tricuspid isthmus (CTI) using the study device.EIVOM could be performed additionally before or after PFA at the operator's discretion.
Undergo PVI with the study device
Primary Effectiveness Endpoint with Treatment Success.
Number of Participants free from Arrhythmia, Re-ablation, Cardioversion, and AAD use.
Time frame: Completion of treatment 360 days compared with the baseline
Primary Safety Endpoint with Safety events related to AF catheter ablation.
Number of Participants with following device or procedure-related serious Composite Adverse Events (CAEs).
Time frame: Completion of treatment 360 days compared with the baseline
Secondary Effectiveness Endpoint with Chronic Success.
Number of Participants with Chronic Success, Freedom from any documented AF, AFL or AT episode lasting ≥10s via 12-lead ECG or ≥30s via Holter (or other continuous rhythm monitoring device) on/off AADs after the blanking period to Day 360.
Time frame: Completion of treatment 360 days compared with the baseline.
Secondary Safety Endpoint with Non-SAE.
Number of Participants with Non-Serious Composite Adverse Event
Time frame: Completion of treatment 360 days compared with the baseline
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.
Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 28 months is above that.
Counting every sponsor, half of 1,049 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston Scientific Corporation →